Please go to the PowerPak homepage
and select a course.
Non-Valvular Atrial Fibrillation:
Improving Detection of Undiagnosed Disease and Optimizing Treatment Strategies for Stroke Prevention: Ask the Experts Presentation
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb and Pfizer Alliance.
Registration & Date of Activity
Wednesday, December 14, 2022
2:00 - 3:30 PM ET
Brian T. Cryder, PharmD, BCACP
Professor of Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove, IL
Ambulatory Care Pharmacist, Chronic Disease Management
Advocate Aurora Health
Kathleen A. Lusk, PharmD, BCPS, BCCP
Associate Professor and Vice Chair, Department of Pharmacy Practice
University of the Incarnate Word Feik School of Pharmacy
Adjunct Assistant Professor, Division of Cardiology, Department of Medicine
UT Health San Antonio
San Antonio, TX
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.5 hours (0.15 ceu)
Estimated time to complete activity: 90 minutes
Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information: There is no fee for this educational activity.
Type of Activity: Application
HOW TO EARN CREDIT
Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the webinar; and 3) complete the posttest and evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.
Get your questions answered by pharmacist experts!
National guidelines for the management of non-valvular AF (NVAF), which is the most common type of AF, now recommend direct-acting oral anticoagulants (DOACs) over warfarin in patients who are eligible for oral anticoagulation for stroke prevention. There are many factors to consider when choosing an anticoagulant in this population, and making evidence-based, patient-specific decisions in this arena can be challenging. Stroke risk, bleeding risk, dosing regimen/ease of adherence, drug interactions, and patient comorbidities may all play a role in the anticoagulant selection process. This interactive webinar will provide the opportunity to ask questions about current management strategies for non-valvular atrial fibrillation (NVAF). The presentation, which will afford greater opportunities to ask questions, will cover the latest science on the consequences of undiagnosed/untreated NVAF, identification strategies and risk factors, and considerations for anticoagulant selection to ensure early and appropriate NVAF treatment for optimal stroke prevention.
Upon completion of this program, participants should be better able to:
- Discuss the consequences of NVAF in patients who are undiagnosed or untreated
- Summarize different AF screening methods and opportunities to improve AF detection
- Differentiate between direct-acting oral anticoagulants used for NVAF and the rationale for their use in stroke prevention
- Formulate strategies to optimize individualized anticoagulant selection and patient management to enhance treatment outcomes for NVAF
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5